207 related articles for article (PubMed ID: 19129046)
21. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
22. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
Jörgens S; Wassmer G; König F; Posch M
Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
[TBL] [Abstract][Full Text] [Related]
23. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
24. Adaptive seamless designs: selection and prospective testing of hypotheses.
Jennison C; Turnbull BW
J Biopharm Stat; 2007; 17(6):1135-61. PubMed ID: 18027222
[TBL] [Abstract][Full Text] [Related]
25. Power and sample size considerations in clinical trials with competing risk endpoints.
Maki E
Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
[TBL] [Abstract][Full Text] [Related]
26. Statistical inference for clinical trials with binary responses when there is a shift in patient population.
Yang LY; Chi Y; Chow SC
J Biopharm Stat; 2011 May; 21(3):437-52. PubMed ID: 21442518
[TBL] [Abstract][Full Text] [Related]
27. Some challenges with statistical inference in adaptive designs.
Hung HM; Wang SJ; Yang P
J Biopharm Stat; 2014; 24(5):1059-72. PubMed ID: 24915027
[TBL] [Abstract][Full Text] [Related]
28. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
Shan G
J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
[TBL] [Abstract][Full Text] [Related]
29. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
Li W; Chen C; Li X; Beckman RA
Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
[TBL] [Abstract][Full Text] [Related]
30. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of matched pair designs with two binary endpoints.
Jiang Y; Xu J
Stat Methods Med Res; 2017 Dec; 26(6):2526-2542. PubMed ID: 26294329
[TBL] [Abstract][Full Text] [Related]
32. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
33. Adaptive designs for single-arm phase II trials in oncology.
Englert S; Kieser M
Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
[TBL] [Abstract][Full Text] [Related]
34. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
Liu Q; Li G; Anderson KM; Lim P
J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
[TBL] [Abstract][Full Text] [Related]
35. An alternative phase II/III design for continuous endpoints.
Huang WS; Liu JP; Hsiao CF
Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
[TBL] [Abstract][Full Text] [Related]
36. Adaptive designs from a Data Safety Monitoring Board perspective: Some controversies and some case studies.
Turnbull BW
Clin Trials; 2017 Oct; 14(5):462-469. PubMed ID: 28178849
[TBL] [Abstract][Full Text] [Related]
37. Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.
Ryeznik Y; Sverdlov O; Hooker AC
AAPS J; 2017 Dec; 20(1):24. PubMed ID: 29285730
[TBL] [Abstract][Full Text] [Related]
38. On the efficiency of adaptive sample size design.
Cui L; Zhang L
Stat Med; 2019 Mar; 38(6):933-944. PubMed ID: 30450621
[TBL] [Abstract][Full Text] [Related]
39. Multi-stage enrichment and basket trial designs with population selection.
Li W; Zhao J; Li X; Chen C; Beckman RA
Stat Med; 2019 Dec; 38(29):5470-5485. PubMed ID: 31621949
[TBL] [Abstract][Full Text] [Related]
40. A modified varying-stage adaptive phase II/III clinical trial design.
Dong G; Vandemeulebroecke M
Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
